GREENWOOD VILLAGE, Colo.,
May 17, 2011 /PRNewswire/ -- Ampio
Pharmaceuticals, Inc. (OTC Bulletin Board: AMPE)("Ampio" or the
"Company"), a clinical stage developer of new uses for previously
approved drugs and new molecular entities ("NMEs"), announces that
its common stock has been approved for listing on the NASDAQ
Capital Market. The shares are scheduled to trade under the
ticker symbol "AMPE" and the Company understands that trading will
commence on that market in the coming days.
"The Company is pleased to make the transition to NASDAQ and
raise our profile in the investment community," commented
Don Wingerter, Ampio's chief
executive officer. "We believe being listed on the Nasdaq Capital
Market will provide Ampio with greater visibility, additional
liquidity for our common stock, and opportunities to expand our
investor base." Pending the listing change, Ampio's common stock
will continue to trade on the OTC Bulletin Board.
About Ampio
The company is currently performing a phase II clinical trial
for the treatment diabetic macular edema and is evaluating the data
from a recently completed phase III clinical trial for the
treatment of premature ejaculation. Ampio Pharmaceuticals, Inc.
develops innovative proprietary drugs for metabolic disease, eye
disease, kidney disease, inflammation, CNS disease, and male sexual
dysfunction. By concentrating on development of new uses for
previously approved drugs, approval timelines, costs and risk of
clinical failure are reduced because these drugs have strong
potential to be safe and effective while their shorter development
times can significantly increase near term value. A key strategy
includes actively exploring partnership, licensing and other
collaboration opportunities to maximize Ampio's product development
programs. For more information about Ampio, please visit our
website, www.ampiopharma.com.
Forward-Looking Statements
Ampio's statements in this press release that are not historical
fact and that relate to future plans or events are forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. These forward-looking statements include our
expectation of commencing trading on the Nasdaq Capital Market in a
timely manner. Forward-looking statements involve risks and
uncertainties, such as unexpected delays in the listing process,
changes in business conditions, and similar events. The risks and
uncertainties involved include those detailed from time to time in
Ampio's filings with the Securities and Exchange Commission,
including Ampio's Annual Report on Form 10-K and Quarterly Reports
on Form 10-Q.
Contact:
Investor Relations
Ampio Pharmaceuticals, Inc.
303-418-1000
SOURCE Ampio Pharmaceuticals, Inc.